ESMO 2024 | The role of ctDNA as a biomarker in bladder cancer treatment decisions
Alexandra Drakaki, MD, PhD, University of California Los Angeles, Los Angeles, CA, emphasizes the critical role of circulating tumor DNA (ctDNA) as a biomarker across various cancers. ctDNA provides valuable insights into treatment efficacy and future patient management in the adjuvant setting. The ongoing MODERN trial (NCT05987241) aims to refine treatment strategies based on ctDNA status, while the NIAGARA trial (NCT03732677) investigates the effects of immunotherapy administered before and after surgery. She also notes the challenges in selecting the optimal ctDNA analysis platform, mentioning various technologies like GRAIL, Signatera, FoundationOne, and Guardant360, and highlighting the need for a method capable of identifying mutations at the single-cell level for enhanced precision in cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
